Zheng Quan Shi Bao Wang·2025-10-08 09:21Core Viewpoint - InnoCare Pharma Inc., a wholly-owned subsidiary of Innovent Biologics, has signed a licensing agreement with Zenas BioPharma, allowing Zenas to develop, produce, and commercialize the product Orelabrutinib and two preclinical assets, which is expected to accelerate the global development and commercialization of these products [1] Group 1: Licensing Agreement Details - The agreement includes an upfront payment of $100 million and 7 million shares of common stock, with potential milestone payments exceeding $2 billion [1] - The company is entitled to receive tiered royalties of up to a high double-digit percentage based on the annual net sales of the licensed products [1] - The agreement is effective from the date of signing and will last until the expiration of the sales license for the licensed products [1] Group 2: Product Information - Orelabrutinib (also known as Ibrutinib) is a late-stage clinical product that is a highly CNS-penetrant, selective, irreversible oral small molecule BTK inhibitor with potential best-in-class advantages [1] - The licensing agreement is expected to have a positive impact on the company's future performance [1]